How the Treatment of Lung Cancer Has Been Transformed in the Era of Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs Roy Herbst and David Rimm review how biomarker testing has transformed the way patients with lung cancer are treated, and how both medical oncologists and pathologists contribute to these changes.
Ken Schaecher, MD, presents his own personal opinion on the challenges of concerns related to costs of treatment by oncologists and why they should not ignore them. Supported through funding from Incyte
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.